Drug intelligence / Profile preview

SBC291

Development stage: Preclinical
Lead developer: SunRegen Healthcare
Modality: Small Molecules

Overview

SBC291 is a small molecule drug candidate being developed by SunRegen Healthcare for the treatment of various neurodegenerative diseases. It belongs to a series of compounds designed to leverage the neuroglobin pathway and chaperone proteins to provide neuroprotective, neurorescuing, and neurotrophic effects. While SunRegen's lead programs (such as SBC003) focus on ophthalmic conditions like Retinitis Pigmentosa and Macular Degeneration, the SBC291 program represents an expansion of this therapeutic platform into broader neurodegenerative disorders. The compound aims to mitigate neuronal damage and promote cell survival by modulating endogenous protective pathways.

Targets

HSP60 (60 kDa heat shock protein, mitochondrial)NGB (Nucleolar GTP-binding protein 1)

Beyond the preview

Go deeper on SBC291.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBC291.

Explore the full profile